In: Annals of Oncology, 2013, vol. 24, no. 2, p. 391-397
|
In: Annals of Oncology, 2012, vol. 23, no. 11, p. 2852-2858
|
In: Annals of Oncology, 2008, vol. 19, no. 6, p. 1110-1116
|
In: Annals of Oncology, 1996, vol. 7, no. 5, p. 471-479
|
In: Annals of Oncology, 2007, vol. 18, no. 9, p. 1493-1499
|
In: Annals of Oncology, 2005, vol. 16, no. 12, p. 1882-1888
|
In: Annals of Oncology, 1998, vol. 9, no. 9, p. 973-976
|
In: Annals of Oncology, 2008, vol. 19, no. 8, p. 1393-1401
|
In: Annals of Oncology, 2007, vol. 18, no. 5, p. 859-867
|
In: Histopathology, 2011, vol. 59, no. 5, p. 965–974
Aims: Medullary breast cancer (MBC) is a biologically distinct subtype of breast cancer characterized by prominent lymphocytic infiltrates and a favourable clinical outcome. Tumour-infiltrating CD8+ effector T cells may contribute to the good prognosis of this type of cancer; however, certain subtypes of lymphocyte, such as FoxP3+ regulatory T cells (Tregs), can also suppress antitumour...
|